Amyris Biotechnologies creates renewable products, focusing on fuels and chemicals. The company is developing renewable fuels that reduce lifecycle (GHG) emissions 80%. The fuel source is special in that it is compatible with current gasoline engines, and can be distributed with existing petroleum infrastructure.

Amyris is also developing semi-synthetic artemisinin, a key ingredient in first-line malaria treatments, in hopes of creating a complementary source of non-seasonal, high-quality, affordable artemisinin. This source would supplement the current botanical supply, offering millions of people infected with malaria the chance to gain consistent and reliable access to lower-cost, life-saving Artemisinin-based Combination Therapies (ACTs). Amyris produces environmentally friendly chemicals for a variety of consumer products and industrial applications currently dependent on petrochemical components.

Company Growth (employees)
Emeryville, US
Size (employees)
440 (est)+6%
Amyris was founded in 2003 and is headquartered in Emeryville, US

Amyris Office Locations

Amyris has an office in Emeryville
Emeryville, US (HQ)
100 5885 Hollis St

Amyris Financials and Metrics

Amyris Financials

Amyris's revenue was reported to be $67.2 m in FY, 2016

Revenue (Q3, 2017)

24.2 m

Gross profit (Q3, 2017)

24.2 m

Gross profit margin (Q3, 2017), %


Net income (Q3, 2017)

(70.6 m)

EBIT (Q3, 2017)

(24.1 m)

Market capitalization (11-Dec-2017)

135.1 m

Cash (30-Sep-2017)

15.9 m


228.4 m
Amyris's current market capitalization is $135.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


41.1 m43.3 m34.2 m67.2 m

Revenue growth, %


Cost of goods sold

38.3 m33.2 m37.4 m56.7 m

Gross profit

2.9 m10.1 m(3.2 m)10.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


7 m6 m9.3 m16.3 m7.9 m7.8 m8.6 m8.8 m9.6 m26.5 m13 m25.7 m24.2 m

Cost of goods sold

8.3 m6.2 m7.5 m10.1 m6.6 m11 m8.5 m11.2 m7.9 m14.9 m12.8 m17.3 m

Gross profit

(1.3 m)(195 k)1.8 m6.2 m1.2 m(3.1 m)136 k(2.4 m)1.7 m11.7 m212 k8.4 m24.2 m

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


6.9 m42 m12 m27.2 m

Accounts Receivable

62.8 k


9.5 m6.5 m5.9 m6.2 m

Current Assets

36.9 m73.6 m35.7 m59.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


5.8 m47.8 m88.8 m67.2 m43.8 m10.9 m10.9 m7.8 m822 k582 k1.3 m5.1 m15.9 m

Accounts Receivable

(11.1 m)


7.9 m11.1 m14.8 m16.7 m11.4 m11.1 m11.1 m7.6 m10 m7.9 m7.1 m5.7 m6.4 m

Current Assets

25.3 m73.8 m116.8 m102.9 m69.3 m36.1 m34.6 m27.7 m21.5 m21.1 m24.1 m41 m62.3 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (234.9 m)2.2 m(218.1 m)(97.3 m)

    Depreciation and Amortization

    16.6 m15 m12.9 m11.4 m

    Accounts Receivable

    (4.4 m)(1.2 m)4.9 m(9.3 m)

    Accounts Payable

    (2.6 m)(3.2 m)4.4 m6.4 m
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (24.2 m)16.4 m(35.5 m)(36.7 m)(52.3 m)(99.4 m)(176.1 m)(15.3 m)(28.9 m)(48.6 m)(37.4 m)(70.6 m)

    Depreciation and Amortization

    6.8 m9.9 m2.9 m5.7 m8.6 m2.7 m

    Accounts Receivable

    6 m5.2 m(1.5 m)(183 k)(1.9 m)4.9 m(11.1 m)


    6.4 m
      Y, 2017


      -9.5 x


      -2.2 x

      Financial Leverage

      -0.7 x
      Show all financial metrics

      Amyris Market Value History

      Amyris's Web-traffic and Trends

      Amyris Online and Social Media Presence

      Amyris News and Updates

      Synthetic Biology 2017 Global Key Players –Amyris, Inc. (U.S.), DowDuPont (U.S.), GenScript USA Inc. (U.S.), Intrexon Corporation (U.S.), Integrated DNA Technologies (IDT) (U.S.) Market Analysis And Forecast To 2022

      Wiseguyreports.Com Adds “Synthetic Biology-Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

      Amyris Company Life and Culture

      You may also be interested in